Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target.
about
The Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsIDO2 in Immunomodulation and Autoimmune DiseaseIDO2: A Pathogenic Mediator of Inflammatory AutoimmunityResearch progress of indoleamine 2,3-dioxygenase inhibitorsNanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitorsThe role of placental tryptophan catabolismA biological basis for depression in pancreatic cancer.Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotionIDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype.Tryptophan-degrading enzymes in tumoral immune resistance.Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.Kynurenine and uric acid levels in chronic myeloid leukemia patients.Indoleamine 2,3-dioxygenase: is it an immune suppressor?Neutrophils are Essential in Short Hairpin RNA of Indoleamine 2,3- Dioxygenase Mediated-antitumor EfficiencyThe SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.Posttranslational modification of indoleamine 2,3-dioxygenase.Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.Altered tryptophan metabolism in human meningioma.Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses.CXCR3 ligands promote expression of functional indoleamine 2,3-dioxygenase in basal cell carcinoma keratinocytes.Effector CD4 and CD8 T cells and their role in the tumor microenvironment.Insights into therapy: tryptophan oxidation and HIV infection.Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation.Discovery of IDO1 Inhibitors: From Bench to Bedside.A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss of Function Polymorphisms and Indoleamine-2,3-Dioxygenase-2.Metabolic Barriers to T Cell Function in Tumors.Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.Lipopolysaccharide shock reveals the immune function of indoleamine 2,3-dioxygenase 2 through the regulation of IL-6/stat3 signalling
P2860
Q26765247-E04C5813-6FD3-42C7-A9EC-0187EA3C1C22Q27006786-4519EDD1-9015-4126-9417-3CCC041F77D0Q28069295-5BAC2341-11AF-4B01-8239-1A54BECF8FB6Q28257093-8BE754C9-78B4-4B2B-B9FE-19B7F9AAE2E6Q28818166-AF0EBA36-5C82-48DA-822A-680AF5A3E8E1Q33657987-261CAC7C-1A28-469C-A57E-C27AC4DB31DEQ33960726-C9070A51-CD2D-4E1F-973C-EA53DB4C4E45Q34276759-C8CC237E-97B8-41FB-AC98-5D4B4F101233Q34319398-25EBD514-B63D-4F4D-A460-B2EED5C83705Q34393455-675E98CC-260F-4BAB-8879-2DA713A524BEQ34396547-DC563622-8C33-4B12-815F-94F1FFDA6E2EQ34669312-F6405FF8-00A0-4139-A333-57E253D57311Q34776749-891AAB86-24DE-4E15-809A-CE1366370E00Q35042385-4BC4F5EF-163F-4FB0-BBF7-1A938F33297BQ35261110-AC081C60-AFEA-41BB-B2B8-1684D5A4E744Q35507380-E31439CA-C1A1-47C7-B2F4-D3935D9AFD96Q37362632-B017B886-1264-4666-9EBD-702CB017D8E9Q37507487-BBDDBA98-EF56-4D7C-929F-06E7ED9AB9C2Q37528354-1DAC5310-6F9C-4DEC-B792-3345577FBE15Q37990434-B52B65CD-0F65-45F7-B8C7-792D034B6E20Q37998306-AF2C0419-BA82-4EFA-B3B4-07DD4018C40EQ38047057-22B366A5-4ECA-4702-9F6E-50F2C16F39DAQ38150700-BF26B436-B1E5-4B4F-BAFF-06E55A0EAB5EQ38571347-26E3E138-E53E-48BD-8455-13322A45C7C8Q39178061-B6E8BBC0-37C5-4D28-B7A7-028061C5172EQ39544673-8767158E-67EE-4080-AEAA-52A1287C28B9Q41812172-109748AE-F106-416E-BFBE-4EA778800242Q42490694-9714C700-9D52-461E-95A8-4FE0FADF44CCQ42952683-CD232075-00BD-4DB3-85C2-A8DFA2D1748BQ43059416-B52F7CE0-5510-4934-9CD5-492DBBEA5F1AQ46698119-AB118DC4-F63D-41A6-94B4-3EBBA2BC770DQ47547812-39BE33B9-089E-449D-85FA-5A42F77353B0Q50095635-3B8F80A3-3212-4897-92D3-565C8E6F0656Q50133232-8A4948FB-2A2E-4047-BC05-04584E9C018FQ50136955-61A21C1E-1728-4186-88A0-B84BADC30676Q58107327-2EE036CA-39A5-4EBD-90CF-23BA4CC69212
P2860
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Genotyping and expression anal ...... ancer: a novel, active target.
@en
type
label
Genotyping and expression anal ...... ancer: a novel, active target.
@en
prefLabel
Genotyping and expression anal ...... ancer: a novel, active target.
@en
P2093
P2860
P1476
Genotyping and expression anal ...... ancer: a novel, active target.
@en
P2093
Agnieszka K Witkiewicz
Alexander J Muller
Charles J Yeo
Christina L Costantino
George C Prendergast
Jonathan R Brody
Richard Metz
P2860
P304
781-7; discussion 787-9
P356
10.1016/J.JAMCOLLSURG.2008.12.018
P577
2009-05-01T00:00:00Z